Atrium Therapeutics IncRNA
Price$8.28

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $18.8M+72.1% YoYTTM through 31 Dec 2025
Net Income -$684.6MTTM through 31 Dec 2025
Free Cash Flow -$663.8MTTM through 31 Dec 2025

Margins

Current
Operating Margin-3,977.3%
Net Margin-3,650.4%

Returns

-40.0%ROE
-35.0%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio13.32x
Net Debt-$1.7Bnet cash position
Cash & Equivalents$382.5M

Quality Metrics

Altman Z-Score-1.04
Piotroski F-Score3 / 9
FCF Margin-3,539.1%
Rule of 40-3,523.9

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $18.8M
Diluted EPS-$4.97TTM
'20'21'22'23'24'25
FY2025: $-4.97

Dividend

No dividend

Capital Allocation

Capex Intensity39.5%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.